<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Topotecan, a <z:chebi fb="0" ids="50276">topoisomerase-I inhibitor</z:chebi> is an active drug in the treatment of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>To evaluate its toxicity and efficacy in a combination regimen with <z:chebi fb="0" ids="28680">cytarabine</z:chebi>, we conducted a clinical phase I/II trial in patients with relapsed <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) or relapsed or newly diagnosed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Twenty-one patients (11 AML, 10 MDS/CMML) entered the study and were treated with 1.25 mg/m2 topotecan as continuous intravenous infusion daily for 5 days and <z:chebi fb="0" ids="28680">cytarabine</z:chebi> 1.0 g/m2 by infusion over 2 h daily for 5 days (TA) </plain></SENT>
<SENT sid="3" pm="."><plain>Cycles were repeated on day 28 </plain></SENT>
<SENT sid="4" pm="."><plain>The median observation time was 131 weeks (range: 36-196 weeks) </plain></SENT>
<SENT sid="5" pm="."><plain>A total of 37 cycles of TA were administered </plain></SENT>
<SENT sid="6" pm="."><plain>In 1 patient, the dose of TA had to be reduced and in 1 patient, there was a treatment delay for the second cycle, both because of hematologic toxicity </plain></SENT>
<SENT sid="7" pm="."><plain>The most frequent non-hematologic side-effect of TA was <z:hpo ids='HP_0001945'>fever</z:hpo>, which occurred in 17 patients (89%) with temperatures over 38 degrees C </plain></SENT>
<SENT sid="8" pm="."><plain>None of the patients died due to any treatment-related toxicities, but 2 patients (10%) died within 1 month due to disease progression </plain></SENT>
<SENT sid="9" pm="."><plain>A CR was achieved in 7 patients (33%), 3 of whom were <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and 4 AML </plain></SENT>
<SENT sid="10" pm="."><plain>A partial remission was reported in 8 patients (38%), no change of disease in 2 patients (10%) and progressive disease in 4 patients (19%) </plain></SENT>
<SENT sid="11" pm="."><plain>The median remission duration was 18 weeks (range 2-161 weeks) for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients and 11 weeks (range 2-49 weeks) for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients </plain></SENT>
<SENT sid="12" pm="."><plain>The time to progression for patients of 60 years and older (n = 10) was 16 weeks (range 2-49 weeks) and the survival was 32 weeks (range 2-119 weeks) </plain></SENT>
<SENT sid="13" pm="."><plain>TA is a feasible and efficacious chemotherapeutic combination for the treatment of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="14" pm="."><plain>For patients of 60 years and older, this regimen is also a safe option </plain></SENT>
</text></document>